Kornimate/medical-research-clean huggingface dataset:
analysis of the incidence of expression of tumor antigens in pathologically proven stage i, ii and iii non-small cell lung cancer(nsclc) in asiatic patients

Conditions: Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Summary: this study aims to investigate the expression of melanoma-associated antigen 3 (mage-a3), melanoma-associated antigen c2 (mage-c2), new york esophageal squamous cell carcinoma 1 (ny-eso-1), l antigen family member 1 (lage-1), wilms' tumor gene (wt1) and prame (preferentially expressed antigen of melanoma) tumor antigens in a large number of pathologically proven stage i, ii and iii nsclc samples of asiatic patients.

this study will be based upon the analysis of samples and patient-related data already available at the various investigation sites. there will be no study treatment and no study-specific procedure carried out on the patients. clinical data collected will include patient demographics (age, gender), tumor, node, metastasis (staging system) \[tnm stage\], histopathologic description and the patient smoker status. strict anonymity of patient data will be maintained. this retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.

Eligibility criteria:
inclusion criteria: for inclusion of a tissue sample, all of the following criteria must be met: * the patient had pathologically proven stage i, ii or iii nsclc. * all the data required are available from patient's records. * many patients may no longer be alive, or no longer be in contact with the investigation sites. thus, patients will not be required to give their informed consent before inclusion in the study. exclusion criteria: * not applicable

Keywords: tumor antigens asiatic patients reverse transciptase-polymerase chain reaction (rt-pcr) non-small cell lung cancer (nsclc)
molecular imaging-based dose escalation in hpv negative patients with locally advanced scc of the oropharynx

Conditions: Head and Neck Cancer

Summary: phase i study to assess the feasibility (i.e. early toxicity) of molecular imaging-based dose escalation in hpv negative patients with locally advanced scc of the oropharynx.

the objective is to assess the feasibility (i.e. early toxicity) of an adaptive dose escalation through 18f-fdg-pet-based dose painting by numbers in 10 hpv negative patients with locally advanced squamous cell carcinoma of the oropharynx. treatment will be delivered with helical tomotherapy® or volumetric-modulated arc therapy (vmat). dose adaptation will be performed at 2 time-points with per-treatment 18f-fdg-pet/ct scans.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients with squamous cell carcinoma of the oropharynx, hpv-negative (p16 assay) * t size of 3 cm or more in greatest dimension with the exclusion of tumor with bone infiltration * n0, n1, n2a, n2b node (ajcc/uicc 7th edition) * no distant metastasis * no contra-indication to concomitant chemotherapy * world health organization (who) performance status of 0 or 1 or karnofsky performance status ≥ 80. * provision of written informed consent exclusion criteria: * patients with induction chemotherapy will not be eligible * previous or concurrent history of cancer, except basal cell skin carcinoma * second primary tumor at the time of diagnosis * previous treatment with surgery, radiotherapy or chemotherapy for head and neck malignancy * any evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease), or psychological disorder * pregnant or lactating women
treatment of renal angiomyolipomas in tuberous sclerosis by beta-blockers

Conditions: Renal Angiomyolipomas; Tuberous Sclerosis

Summary: treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization. development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors. angiomyolipomas have been shown to regress after prolonged treatment with mtor inhibitors (sirolimus), but with a large proportion of secondary effects. we showed recently that beta-blockers were able to induce regression of infantile hemagiomas. consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the presence of beta2 receptors. the aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study.


Eligibility criteria:
inclusion criteria: * tuberous sclerosis patients with one or several angiomyolipomas of a size of at least 4 cms. exclusion criteria: * patients whom ct or mr scan shows one or several intra-lesional aneurisms requiring a preventive embolization. * patients with a retroperitoneal hemorragic complication requiring a preventive embolization. * patients whom biopsy will show an adenocarcinoma, hypertension non controlled, renal failure and severe liver. * diabetic subjects insufficiently controlled. * beta-blockers contra-indication. * psychosis, severe mental disorder. * patient already treated with beta-blockers or mtor inhibitors. * pregnant or nursing women.

Keywords: angiomyolipomas in tuberous sclerosis beta-blockers anti-angiogenic therapies
drug-drug interaction study(lobeglitazone, warfarin)

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and warfarin in healthy subjects.

from day 1 to day 12, lobeglitazone 0.5mg is administered daily to group 1 subjects during period 1. then on day 5,warfarin 25mg is co-administered group 1 subjects at period 1. after 10 day-break, warfarin 25mg is administered group 1 subjects at period 2. on period 2, lobeglitazone is not administered. group 2 is administered in reverse order.

Eligibility criteria:
inclusion criteria: * a healthy male volunteer between 19 and 55 years old. * bmi between 19 and 27. * signed the informed consent form prior to study participation. * able to participate in the entire trial exclusion criteria: * clinically significant hepatic, renal, digestive system, respiratory system, endocrine system, nervous system, hematologic, cardiovascular system, tumor or have history of tumor * clinically significant hemorrhagic disease * genetic problems such as galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption * have hypersensitivity reactions history for lobeglitazone, warfarin, excipient of ip or aspirin, antibiotics * medication which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products within 30 days prior to screening * participated in the other clinical trials and administrated ip within 60 days prior to screening * subject takes ethical drug or herbal medicine within 14 days, otc within 7 days before screening * previously donate whole blood within 60 days or component blood within 30 days * sit sbp \< 90mmhg or sit sbp ≥ 140mmhg or sit dbp \< 60mmhg or sit dbp ≥ 90mmhg * a heavy alcohol consumer (alcohol \> 140 g/week) or cannot stop drinking * a heavy smoker (cigarette \> 10 cigarettes per day) or cannot stop smoking * a heavy caffeine consumer (more than 4cups per a day) or a heavy grapefruit consumer (more than 1cup per a day) or cannot stop having * positive for the triage tox drug on urine * positive for hiv antibody, hbsag, hcv antibody test * ast, alt or total bilirubin \> unl \* 1.5 * estimated gfr \< normal limit * inr, aptt over the normal limit * clinically significant laboratory test result * clinically significant ecg * an impossible one who participates in clinical trial by investigator's decision including other reason

Keywords: lobeglitazone warfarin type 2 diabetes mellitus drug-drug interaction phase 1
study transplanting bone marrow cells into salivary glands to treat dry mouth caused by radiation therapy

Conditions: Head and Neck Cancer; Xerostomia

Summary: the goal of this clinical research study is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stem cells (mscs) into your salivary glands. participants will have head and neck cancer that was treated with radiation therapy, and in this study will: * undergo a collection of bone marrow using a needle; * donate saliva; * undergo a salivary gland ultrasound; and, * complete questionnaires that ask about dry mouth participants can expect to be in this study for up to 30 months. there is no expanded access program available per this protocol.


Eligibility criteria:
inclusion criteria: * history of histological diagnosis of head and neck cancer (hnc) that was treated with radiation therapy and currently clinically or radiologically no evidence of disease (ned) * xerostomia, defined as patient reported salivary function (pre-treatment) ≤ 80% of healthy (pre-radiation) * ≥ 18 years of age, ≤ 90 years of age. * patients ≥ 2 years from completion of radiation therapy for hnc * karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia * willing and able to give informed consent * radiographically confirmed submandibular gland(s) exclusion criteria: * salivary gland disease (i.e., sialolithiasis)
efficacy and tolerability of switching to ziprasidone from other antipsychotics

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in state hospitals this study aims to demonstrate its effectiveness and relative lack of side effects. 75 patients with schizophrenia or schizoaffective disorder who need a change of medication because of ineffectiveness or side effects will be changed to ziprasidone and followed with detailed assessments for eight weeks. the hypothesis is that they will improve and have fewer side effects.

ziprasidone has been found in studies and practice to be efficacious and tolerated well but has not been well studied or well accepted in the very severely ill in state hospitals. this study aims to fill that gap by examining 75 patients with schizophrenia or schizoaffective disorder who require a change of medication because of poor response or unacceptable side effects. after signing consent and having a baseline assessment they will, if necessary, be reduced to one antipsychotic then started on ziprasidone, increasing to 160mg the second day. the one antipsychotic they had been on will be reduced over a week and stopped. the ziprasidone can be increased to 240mg after three weeks if necessary. the study will last eight weeks with efficacy assessed by clinical global impressions (cgi), positive and negative syndrome scale (panss) every two weeks and brief assessment of cognition, calgary depression scale for schizophrenia, personal evaluation of transitions in treatment and medical outcomes study cognitive questions at the beginning and end. side effects will be measured by movement disorder scales (simpson-angus scale for parkinsonism (sanrs), abnormal involuntary movement scale (aims) and barnes akathisia scale (bas)), ecg and weight and blood metabolic measures. the hypothesis is that ziprasidone will be generally effective and that side effects especially metabolic indices will be reduced.

Eligibility criteria:
inclusion criteria: * schizophrenia or schizoaffective * capacity to give consent * stable, on the same medication for a month but only partial response or with unacceptable side effects 18-65 years of age exclusion criteria: * repeated non-compliance * current depot medication * active medical conditions * qtc \>500msec * previous non-response * previous treatment with ziprasidone

Keywords: schizophrenia ziprasidone
thyroid dysfunction and dyslipidemia in patients with chronic kidney diseases

Conditions: CKD

Summary: early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in ckd patients may be highly beneficial to slow progression of ckd. the study will be conducted to investigate thyroid function and lipid profile in patients with chronic kidney disease.

chronic kidney disease\[ckd\] is becoming a serious health problem.the number of people with impaired renal function is rapidly rising, especially in industrialized countries. it is increasing rapidly worldwide at an annual growth rate of 8%. chronic kidney disease \[ckd\] is defined as kidney disease that has been present for months to years. chronic kidney disease \[ckd\] is a complex disease impacting more than twenty million individuals. progression of ckd is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .ckd patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality . ckd affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland.thus,inckd,thyroid hormone metabolism is impaired. . hypothyroidism in patients with renal failure causes many metabolic and clinical problems, and both these diseases can mutually exacerbate their disturbances.. chronic kidney disease has been known to affect thyroid hormones metabolism .low serum level of t3 and t4 are most remarkable laboratorial finding. a high incidence of goiter and nodules on thyroid ultrasonography has been reported in patients with end stage renal failure\[esrf\]. ckd is often associated with dyslipidemia. several factors contribute to these changes. patient with ckd have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. this interferes with uptake of triglyceride rich apo lipoprotein b containing lipoprotein by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in ckd patients may be highly beneficial to slow progression of ckd.

Eligibility criteria:
inclusion criteria: 1. patients with ckd stage (1-5). 2. not known thyroid disorders. 3. not in lipid lowering agents. exclusion criteria: 1. patients with known thyroid disorders, on medication affecting thyroid function and lipid lowering agents are excluded from the study. 2. ckd patients who were or underwent previous dialysis. 3. nephrotic syndrome. 4. obesity. 5. patients on estrogens, corticosteroids, antithyroid drugs, dietary supplements. 6. pregnant woman
evaluation of a patient 'nudge' on engagement in lung cancer screening

Conditions: Lung Cancer

Summary: the purpose of this quality improvement project is to conduct and evaluate the effect of sending an electronic reminder message to patients who qualify for lung cancer screening, haven't had a screening previously, and who have an upcoming scheduled appointment with their doctor.

united states preventive services task force (uspstf) lung cancer screening (lcs) guidelines recommend lcs for those aged 50-80 with at least 20 pack-years smoking history, who currently smoke or quit within the last 15 years. in 2023, our study team found that there are approximately 6,000 - 8,000 kaiser permanente colorado (kpco) members who are unscreened and eligible for lung cancer screening (lcs). in support of kp's population health priority initiative to expand lung cancer screening participation for those who are eligible, our study team was selected to move this work forward in 2024 with feasible implementation opportunities for the kpco lcs operational/institute for health research partnership at its core. the primary objective of this project is to conduct and evaluate a randomized quality improvement pragmatic intervention of a 2-arm electronic message outreach to unscreened lcs members who are eligible for lcs and who have an upcoming scheduled primary care provider (pcp) visit.

Eligibility criteria:
inclusion criteria: qualifies for lung cancer screening based on uspstf criteria (aged 50-80, at least 20 pack years smoking history, currently smoke or quit in the last 15 years); have an upcoming, scheduled primary care visit in a kp clinic in the coming 7-14 days, have not completed a low-dose ct scan. exclusion criteria: * none
a post marketing surveillance program for nutropinaq® in paediatric growth disorders

Conditions: Growth Hormone Disorders

Summary: this study is a multicenter, open label, observational, post marketing surveillance study of nutropinaq® in austria, france, germany, italy, spain, romania and united kingdom to collect long-term safety and effectiveness information on nutropinaq® during treatment of paediatric growth disorders.

the objective of this study is to collect long term safety and effectiveness information on ipsen's growth hormone (gh) nutropinaq® regarding treatment of paediatric growth disorders for which gh is indicated.

Eligibility criteria:
inclusion criteria: * children of either sex who are treated with nutropinaq® for the treatment of growth failure * patients who are willing to comply with follow-up appointments throughout study participation * written informed consent signed by both parents or by the liable parent or by the legal guardian when applicable, and by the child when applicable exclusion criteria: * patients not treated with nutropinaq® * patients with closed epiphyses * patients with active neoplasia
motivation to exercise in people with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the purpose of this research study is to determine the importance and level of physical activity in people with anorexia nervosa.

a laboratory paradigm that uses a progressive ratio computerized work task will be used to determine the reinforcing value of exercise in hospitalized patients with an, both before and after weight gain. in addition, we will examine the relationship between the reinforcing value of exercise and free-living physical activity in this population. we will also examine the relationship between the reinforcing value of exercise and measures of depression, anxiety, and cortisol, which we have found in previous studies to be associated with other measures of physical activity and exercise motivation. in order to determine whether physical activity in women with an differs from that of non-eating disordered women, we will extend studies of physical activity to free-living control participants. all adult patients and controls will undergo body composition assessment once to measure the association between physical activity and percent body fat. finally, to determine the impact of exercise reinforcement and physical activity on outcome in women with an, we will conduct follow-up assessments in all patient participants for one year after discharge from the inpatient treatment unit."

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of anorexia nervosa (except amenorrhea) * female * age 18-45 * medically stable for exercise participation * at a minimum of 75% ideal body weight exclusion criteria: * significant or current past medical illness including diabetes mellitis and heart disease * current or lifetime history or schizophrenia, bipolar disorder, or other psychotic disorder as defined by dsm-iv-tr * current suicidal ideation or recent suicidal behavior (within past 3 months) * drug or alcohol abuse in last 6 months * taking psychotropic medication * pregnancy

Keywords: anorexia nervosa eating disorders exercise physical activity
a study of medical records from children with central precocious puberty (cpp) in china

Conditions: Central Precocious Puberty

Summary: the main purpose is to describe how many children were treated during 24 months or less because of cpp and how treatment worked for them. there are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.

this is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in chinese pediatric participants diagnosed with cpp. this study will enroll approximately 1000 participants. the data available in an existing data source the chinese cpp big data platform database will be analyzed. all the participants will be assigned to a single observational cohort: • pediatric participants with cpp this multi-center trial will be conducted in china. the overall duration of the study will be approximately 3 years.

Eligibility criteria:
inclusion criteria: • participants diagnosed with cpp and treated with gnrha from the centers participating in this study within the chinese cpp big data platform database since 2015 to 2024. cpp diagnosis is based on the clinical assessment and description by cpp specialized doctors. exclusion criteria: * not received gnrha as the treatment for cpp. * no available data for analysis.

Keywords: central precocious puberty
oral low-molecular weight hyaluronic acid in the treatment of atrophic vaginitis

Conditions: Atrophic Vaginitis

Summary: to evaluate the effectiveness of low molecular weight hyaluronic acid oral tablets for the treatment of atrophic vaginitis.


Eligibility criteria:
inclusion criteria: * at least 12 months postmenopausal * mucosal atrophy and the main bothersome related symptoms, such as itching, burning, and dyspareunia.
guangdong uptake of surgery trial

Conditions: Cataract

Summary: the purpose of this study is: 1. to determine whether an educational intervention designed based on studies in the area is effective in increasing acceptance of surgery and presentation to the hospital, when adjusting for a number of potential determinants of service uptake; 2. to assess short-term impact of the educational intervention on knowledge about cataract and attitudes toward locally-available surgical services.

china is home to the 18% of the world's blind people, an estimated 6.6 million. in china, cataract is the leading cause of blindness. in guangdong, current counseling measures for patients diagnosed with cataract are minimal and often lack adequate descriptions of what cataract is, what causes cataract, and benefits/risks of surgery. a counseling session for cataract patients and family members, conducted by a trained nurse during outreach screening, may increase subsequent attendance at pre-operative examination, acceptance of cataract surgery, and attendance at follow-up examinations. an integral part of this counseling is a short movie consisting of testimony from a former cataract patient who underwent surgery ("pseudophakic motivator"). the use of pseudophakic motivators have been shown to be effective in increasing surgical uptake. in addition, a previously validated "barriers questionnaire" will be used to assess predictors of of hospital attendance, surgery acceptance, and follow-up attendance in the categories of cost, transportation, knowledge, and concerns about quality.

Eligibility criteria:
inclusion criteria: * thought by the examiner to have age-related or myopic cataract in one or both eyes * pinhole-corrected visual acuity less than or equal to 6/18. exclusion criteria: * traumatic cataract * inability to give informed consent due to dementia or other reasons.

Keywords: cataract counseling surgical uptake follow-up